Clinical Trials
Braintumor Website

There are 32 trials:
Facility: Dana Farber Cancer Institute
NCT Trial Name# of Centers

NCT02511405

  A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
53

NCT02639546

  iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors
24

NCT03257631

  A Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
21

NCT02650401

  Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
19

NCT02335918

  A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
18

NCT02078648

  Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
16

NCT01748149

  Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas
14

NCT01432171

  Lacosamide for Seizure Prophylaxis in High-Grade Gliomas
13

NCT02285439

  Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors
12

NCT03150862

  A Study Assessing BGB-290 With Radiation and/or Temozolomide (TMZ) in Subjects With Newly Diagnosed or Recurrent Glioblastoma
12

NCT01012609

  External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas
11

NCT01967810

  ANG1005 in Patients With Recurrent High-Grade Glioma
11

NCT02658279

  Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
11

NCT02844439

  Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
10

NCT02423343

  A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioblastoma
10

NCT02017717

  A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients
10

NCT01790503

  A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
9

NCT02977780

  INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
7

NCT02981940

  A Study of Abemaciclib in Recurrent Glioblastoma
7

NCT02684058

  Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG
7

NCT00826241

  Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
6

NCT02852655

  A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
6

NCT02909777

  Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
4

NCT00916630

  Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)
3

NCT03071874

  Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
3

NCT03075072

  Whole Brain Radiation Versus Stereotactic Radiation (SRS) in Patients With 5-20 Brain Metastases: A Phase III, Randomized Clinical Trial
2

NCT03139916

  Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
2

NCT03152318

  A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
2

NCT03279692

  Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
2

NCT02886585

  Pembrolizumab In Central Nervous System Metastases
2

NCT02478164

  Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
2

NCT02287428

  Ph I Personalized NeoAntigen Cancer Vaccine With Radiotherapy for Patients With MGMT Unmethylated, Newly Diagnosed Glioblastoma
1



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites